Emcure Pharmaceuticals Limited has launched an Initial Public Offering (IPO) of 19,375,070 equity shares, totaling ₹19,520.27 million (approximately USD 234 million).
Shardul Amarchand Mangaldas & Co advised Emcure Pharma on this IPO. The advisory team included Nikhil Naredi (Partner), Priya Awasthi (Partner), Rakshita Poddar (Associate), and Manish Soni (Associate).
Khaitan & Co acted as the legal counsel for the bankers, including Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and J.P. Morgan India Private Limited, for this IPO. The transaction team comprised Chirayu Chandani (Partner), Aditya Cheriyan (Partner), Tishita Mukherjee (Senior Associate), Hrithik Khurana (Associate), Kaushlendra Palawat (Associate), and Shreya Iyer (Associate).
The IPO saw an overall subscription of 68.50 times. The retail individual portion was oversubscribed 7.49 times, the QIB portion 190.88 times, non-institutional bidders (bids between 0.20 million and 1.00 million) 39.05 times, and non-institutional bidders (bids above 1.00 million) 55.39 times.
Emcure Pharmaceuticals Limited is a leading pharmaceutical company involved in the development, manufacturing, and global marketing of a wide range of pharmaceutical products across several major therapeutic areas.